|
LIVE WEBINAR: Wednesday, June 14, 2023, 5:00 PM – 6:00 PM Eastern Time
What I Tell My Patients: Faculty Physicians and Nurses Discuss Patient Education About New Treatments and Clinical Trials — Colorectal and Gastroesophageal CancersPart 2 of a 3-Part Complimentary NCPD Webinar Series in Partnership with the 2023 ONS Congress
Join us on Wednesday, June 14th for this NCPD-accredited webinar Faculty
Kristen K Ciombor, MD, MSCI Associate Professor of Medicine Division of Hematology/Oncology Vanderbilt-Ingram Cancer Center Nashville, Tennessee
Amanda K Wagner, APRN-CNP, AOCNP
GI Malignancies The James Cancer Hospital The Ohio State University Columbus, Ohio Moderator Neil Love, MD Research To Practice Miami, Florida Wednesday, June 14, 2023 What I Tell My Patients About ... MODULE 1: The Implications of Tumor Sidedness for Treatment Selection in Metastatic Colorectal Cancer (mCRC) MODULE 2: The Role of BRAF-Targeted Therapy in the Treatment of mCRC MODULE 3: Current and Future Integration of Therapies Targeting HER2 in mCRC MODULE 4: Incidence and Management of Toxicities with Trastuzumab Deruxtecan (T-DXd) MODULE 5: Tolerability of Tucatinib/Trastuzumab MODULE 6: The Role of Immune Checkpoint Inhibitors in the Management of mCRC MODULE 7: Current and Potential Role of Regorafenib and Other Kinase Inhibitors in the Treatment of Relapsed/Refractory (R/R) mCRC MODULE 8: Adjuvant Anti-PD-1 Antibody Therapy for Esophageal Cancer MODULE 9: First-Line Therapy for Metastatic Gastroesophageal Cancers MODULE 10: Tolerability of Immune Checkpoint Inhibitors MODULE 11: Targeted Therapies for HER2-Positive Gastric/Gastroesophageal Junction (GEJ) Cancer MODULE 12: Ramucirumab in Therapy for R/R Gastric/GEJ Cancer MODULE 13: The Role of TAS-102 in the Treatment of Advanced Gastric/GEJ Cancer and CRC MODULE 14: Promising Investigational Strategies for Gastroesophageal Cancers Target Audience
Accreditation Statement Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. FACULTY — Ms Wagner has no relevant conflicts of interest to disclose. The following faculty reported relevant financial relationships with ineligible entities: Dr Ciombor – Advisory Committee: Bayer HealthCare Pharmaceuticals, Exelixis Inc, Incyte Corporation, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Personalis, Pfizer Inc, Replimune, Seagen Inc; Consulting Agreements: Merck, Pfizer Inc; Contracted Research: Array BioPharma Inc, a subsidiary of Pfizer Inc, Bristol Myers Squibb, Calithera Biosciences, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Incyte Corporation, Merck, NuCana, Pfizer Inc, Seagen Inc. MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab US Inc, Gilead Sciences Inc, Grail Inc, GSK, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc, and Zymeworks Inc. RESEARCH TO PRACTICE NCPD PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose. SupportersThis activity is supported by educational grants from Astellas and Seagen Inc. |